Kerri Fitzgerald

DocwireNews

The U.S. Food and Drug Administration (FDA) approved the combination of Darzalex&reg; (daratumumab) plus Velcade&reg; (bortezomib), thalidomide, and dexamethasone for patients with <a href="https://www.docwirenews.com/abstracts/daratumumab-plus-lenalidomide-and-dexamethasone-for-untreated-myeloma/">newly diagnosed multiple myeloma</a> (MM) who are eligible for autologous hematopoietic cell transplantation (AHCT).The decision was based on results from the open-label, randomized, active-controlled,&nbsp;<a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and-after-autologous-stem-cell-transplantation-for-newly-diagnosed-multiple-myeloma-cassiopeia-a-randomised-open-label/">phase III CASSIOPEIA trial</a>, which compared induction and consolidation treatment with daratumumab 16 mg/kg in combination with bortezomib, thalidomide, and dexamethasone versus bortezomib, thalidomide, and dexamethasone alone in 1,085 patients with newly diagnosed MM who were transplant-eligible.<h2>Improved survival with the addition of daratumumab</h2>The results indicated an improvement in progression-free survival (PFS) in those receiving the daratumumab combination. After a median follow-up of 18.8 months, the median PFS was not reached in either cohort.The addition of daratumumab reduced the risk of progression or death by 53% compared with bortezomib, thalidomide, and dexamethasone alone (hazard ratio = 0.47; 95% CI, 0.33-0.67; P&lt;0.0001). The stringent complete response rate at 100 days post-AHCT was 28.9% in the daratumumab cohort and 20.3% in the bortezomib, thalidomide, and dexamethasone alone group.The most common adverse events (AEs) experienced by patients receiving daratumumab, bortezomib, thalidomide, and dexamethasone were infusion reactions, peripheral sensory neuropathy, constipation, asthenia, nausea, peripheral edema, neutropenia, thrombocytopenia, pyrexia, and paresthesia. There were no significant differences in the number or type of serious AEs experienced in the two treatment arms.

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

FDA Approves Darzalex® Combo for Transplant-Eligible Patients With Multiple Myeloma

Oncology

The U.S. Food and Drug Administration (FDA) approved the combination of Darzalex® (daratumumab) plus Velcade® (bortezomib), thalidomide, and dexamethasone for patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe